AstraZeneca enters preclinical cell therapy deal with Canadian biotech

Paul Schloesser

Associate Editor

Canadian cell therapy biotech Sernova announced a preclinical research deal with AstraZeneca that will see how Sernova’s implantable medical device works in combination with cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca enters preclinical cell therapy deal with Canadian biotech

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

As­traZeneca en­ters pre­clin­i­cal cell ther­a­py deal with Cana­di­an biotech

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

AstraZeneca enters preclinical cell therapy deal with Canadian biotech

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A